Pfizer, Bristol-Myers to Present Apixaban Data
From Associated Press (August 25, 2010)
NEW YORK -- Pfizer Inc. and Bristol-Myers Squibb Co. will release
late-stage study results for the potential blockbuster blood
thinner apixaban Tuesday at the European Society of Cardiology
Congress 2010.
The New York drugmakers said Wednesday the study compared apixaban with aspirin in patients with atrial fibrillation, or an irregular heartbeat, who are unsuitable for another blood thinner, warfarin.
Results will be presented in Stockholm.
In June, the companies said the study was stopped early due to evidence it reduced risk of stroke and dangerous blood clots, compared to aspirin.
In March, the companies said a separate late-stage study showed apixaban was more effective than Sanofi-Aventis’ Lovenox in a late-stage clinical trial that compared the drugs' ability to reduce blood clots in the legs or lungs, also called venous thromboembolisms, along with deaths in patients undergoing knee replacement operations.
Shares of Pfizer, the world's largest drugmaker, rose 21 cents
to $16.03 in afternoon trading. Bristol-Myers shares rose 2 cents
to $26.04.
Posted: August 2010
